JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265130

Human PPP3CA (Calcineurin A) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(1 Publication)

PPP3CA KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

Alpha isoform formerly PPP2B, CALN, CALNA, CALNA 1, CAM-PRP catalytic subunit, CNA, CNA 1, CNA alpha, Calcineurin A alpha, Calcineurin A1, CalcineurinA, Calmodulin-dependent calcineurin A subunit alpha isoform, PP2BA_HUMAN, PPP2B, Ppp3ca, Protein phosphatase 2B catalytic subunit, Protein phosphatase 3 (formerly 2B) catalytic subunit alpha isoform, Protein phosphatase 3 catalytic subunit alpha isoform PPP3CA, Protein phosphatase 3 catalytic subunit alpha isozyme, Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform

4 Images
Western blot - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130)
  • WB

Lab

Western blot - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130)

Lanes 1- 2 : Merged signal (red and green). Green - ab52761 observed at 59 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (ab8245) observed at 37 kDa.

ab52761 was shown to react with Calcineurin A in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab265130 (knockout cell lysate ab257181) was used. Wild-type HeLa and PPP3CA knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab52761 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) overnight at 4° at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-Calcineurin A antibody [EP1669Y] (<a href='/en-us/products/primary-antibodies/calcineurin-a-antibody-ep1669y-ab52761'>ab52761</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

PPP3CA knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human PPP3CA (Calcineurin A) knockout HeLa cell line (ab265130)

Predicted band size: 59 kDa

Observed band size: 59 kDa

false

Western blot - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130)
  • WB

Lab

Western blot - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130)

Lanes 1- 2 : Merged signal (red and green). Green - ab109412 observed at 59 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (ab8245) observed at 37 kDa.

ab109412 was shown to react with Calcineurin A in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab265130 (knockout cell lysate ab257181) was used. Wild-type HeLa and PPP3CA knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab109412 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) overnight at 4° at a 1 in 10000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-Calcineurin A antibody [EPR1670(2)] (<a href='/en-us/products/primary-antibodies/calcineurin-a-antibody-epr16702-ab109412'>ab109412</a>) at 1/10000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

PPP3CA knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human PPP3CA (Calcineurin A) knockout HeLa cell line (ab265130)

Predicted band size: 59 kDa

Observed band size: 59 kDa

false

Sanger Sequencing - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130)
  • Sanger seq

Unknown

Sanger Sequencing - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130)

Homozygous : 1 bp deletion in exon 1.

Cell Culture - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130)
  • Cell Culture

Unknown

Cell Culture - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130)

Representative images of PPP3CA knockout HeLa cells, low and high confluency examples (top left and right respectively) and wild-type HeLa cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS XL Core microscope.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1

Antibiotic resistance

Puromycin 1µg/mL

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265130-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265130 Human PPP3CA (Calcineurin A) knockout HeLa cell line", "number":"AB265130-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265130-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265130-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265130 Human PPP3CA (Calcineurin A) knockout HeLa cell line", "number":"AB265130-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PPP3CA
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Calcineurin A also known as PPP3CA is a highly specific protein phosphatase with a pivotal role in cellular signaling. It has a molecular mass of approximately 59 to 61 kDa depending on the isoform. Calcineurin A expression occurs in various tissues including the brain immune cells and cardiac tissues. It acts as the catalytic subunit of the enzyme calcineurin and is important for its function.
Biological function summary

Calcineurin A participates in numerous cellular processes through its phosphatase activity. As part of the calcineurin complex which includes a regulatory subunit it modulates the dephosphorylation of target proteins. This activity enables Calcineurin A to influence activation of T-lymphocytes by dephosphorylating the nuclear factor of activated T-cells (NFAT) a transcription factor responsible for immune response. Calcineurin A also plays a role in neuronal signaling and muscle function.

Pathways

Calcineurin A engages in the calcium signaling pathway which is vital for diverse cellular functions. It is related to proteins like calmodulin which binds calcium ions to activate Calcineurin A. Another important pathway includes the MAPK signaling pathway where Calcineurin A influences various cellular outcomes by regulating different transcription factors. Through these pathways Calcineurin A integrates signals that affect cellular growth survival and differentiation.

Calcineurin A is associated with cardiac hypertrophy and immunosuppressive conditions. In cardiac hypertrophy aberrant Calcineurin A activity leads to changes in heart muscle size and function. The protein also connects to the disorder of immunosuppression through its inhibition by drugs like cyclosporine which are used to prevent transplant rejection by targeting Calcineurin A. This inhibition blocks T-cell activation and provides therapeutic benefits in managing transplant patients.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

BMC cancer 24:508 PubMed39103807

2024

Identification and validation of genes associated with prognosis of cisplatin-resistant ovarian cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Dajiang Liu,Ruiyun Li,Yidan Wang,Dan Li,Leilei Li
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com